Antiviral therapy with imiquimod and cocrystals thereof
AssigneeCelista Pharmaceuticals LLC
InventorsYogesh DANDIKER, Sita DANDIKER
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of inhibiting viral replication by topically administering imiquimod, {1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine} or by administering imiquimod cocrystals (made with ferulic, acetic, tartaric, citric or coumaric acid). Another aspect of the invention is a method of preventing or reducing the severity of an infection by topically administering by imiquimod, or one of these cocrystals. Another aspect is administering imiquimod or one of these cocrystals in a nasal spray.
Claims19
A method of increasing interferon levels in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar.
A method of inhibiting viral replication in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar.
A method of inhibiting SARS-CoV-2 viral replication in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar.
A method of preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar.
A method of reducing the severity of a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar.
A method of treating a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar.
A method of treating Long COVID in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and/or IMQ-Tar.
A method of treating postural orthostatic tachycardia syndrome (POTS) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and/or IMQ-Tar.
A method of treating a viral infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar, wherein the viral infection is selected from the group consisting of chicken pox, shingles, herpes, influenza, HIV/AIDS, viral mononucleosis, viral pneumonia, HPV, MMR, viral gastroenteritis, viral hepatitis, viral meningitis, Zika virus, Dengue virus, and mucormycosis.
A sprayable liquid composition in a spray bottle, the composition comprising an active pharmaceutical ingredient selected from the group consisting of:
- imiquimod, IMQ-Fe, IMQ-Ac, IMQ-Ci, IMQ-Co, and IMQ-Tar, and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.